Changes in Mental Health Drugs Carve-Out Effective July 1, 2010

The Maryland Medicaid Mental Health Formulary Managed Care Carve-Out is being modified effective July 1, 2010. For Managed Care Organization (MCO) members 6 – 17 years old, Intuniv® will be added to the Mental Health Formulary and be billed fee-for-service. For MCO members not in this age range, Intuniv® will continue to be part of their respective MCO’s pharmacy benefit. Intuniv® is an extended release formulation of guanfacine that came on the market in late 2009 with an FDA approved indication only for the treatment of ADHD for patients aged 6-17. As in the past, guanfacine (Tenex®) remains a drug for which coverage is the responsibility of the member’s MCO.

Prescriptions for Intuniv® for HealthChoice members, ages 6-17 with a date-of-service on or after July 1, 2010 must be billed fee-for-service, (BIN 610084, PCN DRMDPROD, Group ID MDMEDICAID), the same as all of the other drugs in the Mental Health Formulary. Prescriptions for Intuniv® for members younger than 6 or older than 17 must be billed to the member’s MCO.

- Attached is the complete table showing the American Hospital Formulary Service (AHFS) therapeutic classes included in the Maryland Medicaid Mental Health Formulary Managed Care Carve-Out. Products are listed alphabetically within each AHFS class. The brand name is used when the drug is not generically available.
- Prescribers are advised to consult the Preferred Drug List (PDL) to determine whether it is necessary to obtain a PA if the drug is non-preferred. The PDL is available online at http://www.dhmh.state.md.us/mma/mpap/druglist.html or at www.Epocrates.com.
- Questions concerning the Advisory should be directed to the Division of Pharmacy Services at 410-767-1455.
Maryland Medicaid Mental Health Formulary
Effective July 1, 2010

Listed on the following pages are mental health drugs which are carved out of the Managed Care Organization (MCO) pharmacy benefit. Some of these drugs are subject to prior authorization requirements of the Preferred Drug List. Refer to http://www.dhmh.state.md.us/mma/mpap/prefdruglist.html for a complete listing of all drugs subject to preferred drug list requirements.

All drugs from American Hospital Formulary Service (AHFS) therapeutic classes included in the Mental Health Formulary, including specific drugs that may not be listed below, are carved out of the MCO pharmacy benefit and are payable as fee-for-service through Maryland Medical Assistance, unless otherwise noted.

The following seven drugs, which may be used for some mental health indications, are not payable fee-for-service (unless otherwise noted) and are the responsibility of the HealthChoice MCOs for their enrollees, regardless of the prescriber.

Leuprolide acetate*
Naltrexone
Clonidine
Medroxyprogesterone*
Guanfacine*

* When used for the treatment of adult males with certain diagnosed behavioral disorders, these two drugs will be paid fee-for-service, but will require preauthorization (PA) through the University of Maryland School of Pharmacy CAMP program at 410-706-3431.

* Generic guanfacine (Tenex) remains a drug for which coverage is the responsibility of the member’s Managed Care Organization. For recipients 6 – 17 years old, the extended release form of guanfacine (Intuniv) will be added to the mental health formulary and be billed fee-for-service. For individuals not in this age range, Intuniv will continue to be part of the MCO pharmacy benefit.

Please note: Brand drugs which currently do not have a generic equivalent are listed by brand name in italics. Those drugs currently available generically are listed by generic name. All brand drugs, which are available as multi-source generics, require prior approval and completion of a Maryland Medwatch Form unless otherwise noted on the Maryland Medicaid Preferred Drug List. Brand name drugs are in italic print.

<table>
<thead>
<tr>
<th>Therapeutic Class</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Alpha Agonists</td>
<td>Intuniv</td>
</tr>
<tr>
<td>AHFS Class No. 240816</td>
<td>Intuniv is the only drug carved out fee-for-service in this AHFS drug class and is only paid fee-for-service for children ages 6 -17</td>
</tr>
<tr>
<td>Benzodiazepines (Anticonvulsants)</td>
<td>clonazepam</td>
</tr>
<tr>
<td>AHFS Class No. 281208</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous Anticonvulsants</td>
<td>Banzel</td>
</tr>
<tr>
<td>AHFS Class No. 281292</td>
<td>carbamazepine</td>
</tr>
<tr>
<td></td>
<td>carbamazepine XR</td>
</tr>
</tbody>
</table>
| Miscellaneous Anticonvulsants | Felbatol  
gabapentin  
Gabitril  
Keppra XR  
lamotrigine  
levetiracetam  
Lyrica  
oxcarbazepine  
Sabril  
Stavzor  
topiramate  
valproate/divalproex  
valproate/divalproex ER  
Vimpat  
zonisamide |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants</td>
<td></td>
</tr>
</tbody>
</table>
amitriptyline  
amoxapine  
Aplenzin  
bupropion  
bupropion SR  
bupropion XL  
citalopram  
clomipramine  
Cymbalta - Clinical criteria apply see  
[http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm](http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm)  
desipramine  
doxepin  
Effexor XR  
fluoxetine  
fluvoxamine  
imipramine  
Luvox CR  
Lexapro  
maprotiline  
Marplan  
mirtazapine  
mirtazapine Soltab  
Nardil  
nefazodone  
nortriptyline  
Parnate  
paroxetine |
### Antidepressants
AHFS Class No. 281604 (continued)

- Paxil CR
- Pexeva
- Pristiq
- protriptyline
- Prozac Weekly
- Sarafem
- sertraline
- Surmontil
- Symbax
- trazodone
- venlafaxine
- Venlafaxine ER

### Antipsychotic Agents
AHFS Class No. 281608

- Abilify - Clinical criteria apply see [http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm](http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm)
- chlorpromazine
- clozapine
- Fanapt
- FazaClo
- fluphenazine
- Geodon
- haloperidol
- Invega
- Invega Sustenna
- loxapine
- Moban
- Orap
- perphenazine
- risperidone
- Risperdal Consta
- Risperdal M-Tab
- Saphris
- Seroquel
- Seroquel XR
- Symbax
- thioridazine
- thiothixene
- trifluoperazine
- Zyprexa - Clinical criteria apply see [http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm](http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm)
- Zyprexa Relprevv - Clinical criteria apply see [http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm](http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm)
- Zyprexa Zydis - Clinical criteria apply see
| Antipsychotic Agents  
<table>
<thead>
<tr>
<th>AHFS Class No. 281608 (continued)</th>
</tr>
</thead>
</table>
| **Amphetamines**  
| AHFS Class No. 282004 |
| amphetamine  
Desoxyn  
dextroamphetamine  
dextroamphetamine/amphetamine  
dextroamphetamine/amphetamine XR  
methamphetamine  
Vyvanse |

| Anorexigenic Agents and Respiratory and Cerebral Stimulants (Anorexigenic Agents are not covered)  
| AHFS Class No. 282092 |
| Concerta  
Daytrana  
Focalin  
Focalin XR  
Metadate CD  
methylphenidate  
Nuvigil  
Provigil  
Ritalin LA |

| Anxiolytics, Sedatives and Hypnotics – Benzodiazepines  
| AHFS Class No. 282408 |
| alprazolam  
chlordiazepoxide  
clorazepate  
Diastat  
diazepam  
Doral  
estazolam  
flurazepam  
lorazepam  
midazolam  
oxazepam  
Restoril 7.5 mg  
Restoril 22.5 mg  
temazepam  
Triazolam |

| Miscellaneous Anxiolytics, Sedatives and Hypnotics  
| AHFS Class No. 282492 |
| Ambien CR  
buspirone  
chloral hydrate  
droperidol  
hydroxyzine  
Lunesta  
meprobamate  
Rozerem |
| Miscellaneous Anxiolytics, Sedatives and Hypnotics | zaleplon |
| AHFS Class No. 282492 (continued) | zolpidem |
| | Zolpimist |
| Antimanic Agents | lithium |
| AHFS Class No. 282800 | |
| Anticholinergic Agents | benztropine |
| AHFS Class No. 283608 | Trihexyphenidyl |
| MAO Inhibitors | Emsam |
| AHFS Class No. 283632 | Emsam is the only drug carved out fee-for-service in this AHFS drug class |
| Central Nervous Systems Agents Misc. | Strattera – Clinical criteria apply see |
| AHFS Class No. 289200 | http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm |
| | Strattera is the only drug carved out fee-for-service in this AHFS drug class. |